Takeda-Logo

SUMMARY →
point 1 point 2 point 3 point 4 point 5
music music
go-home
point 1 point 2 point 3 point 4 point 5
go-home
music music

For Healthcare Professionals Only. Takeda Pharmaceuticals (Asia Pacific) Pte Ltd
10 Marina Boulevard, #15-01 Marina Bay Financial Centre, Tower 2, Singapore 18981
Tel: +65 6808 9500 www.takeda.com
© 2025 Takeda Pharmaceutical (Asia Pacific) Pte Ltd. All rights reserved.
LIVTENCITY and are registered trademarks of Takeda Pharmaceuticals International AG.

For Healthcare Professionals Only. Takeda Pharmaceuticals (Asia Pacific) Pte Ltd
10 Marina Boulevard, #15-01 Marina Bay Financial Centre, Tower 2, Singapore 18981.
Tel: +65 6808 9500 www.takeda.com © 2025 Takeda Pharmaceutical (Asia Pacific) Pte Ltd.
All rights reserved.LIVTENCITY and are registered trademarks of Takeda Pharmaceuticals International AG.

qrcode

Scan/ Click here
for Livtencity
Product Information

Livtencity Singapore Prescribing Information March 2025

Livtencity-Logo

C-APROM/SG/LIV/0006 OCT 2025

WITH LIVTENCITY, YOU SEE THE DIFFERENCE IN POST-TRANSPLANT CMV TREATMENT VS. OTHER ANTIVIRALS

Hospital

AT THE HOSPITAL,

  • More patients achieved CMV clearance at week 81
  • 34.8% reduction in hospitalization rate2
  • With tolerable safety profile3
  • Prevents myelosuppression & nephrotoxicity and bone marrow suppression1
  • Administered orally, unlike IV ganciclovir/foscarnet3
Home

AT HOME,

  • Long-lasting and sustained CMV clearance and symptom control through week 161
  • Improved recovery with 53.8% reduced length of hospital stay2
  • Works for various transplant subpopulations4,5
  • Less treatment discontinuation due to treatment-emergent adverse effects vs. conventional therapy, ganciclovir/valganciclovir and foscarnet6

Abbreviations: CMV, cytomegalovirus; IV, intravenous

References: 1. Avery RK, et al. Clin Infect Dis. 2022;75(4):690-701 and Supplementary data. 2. Hirji I, et al. Transpl Infect Dis. 2023;25(3):e14064. 3. LIVTENCITY. Summary of Product Characteristics. 4. Avery RK, et al. Am J Transplant. 2021;21(suppl 3). 5. Data on File. VV-SUP-86970. Takeda Pharmaceutical. 2021. 6. Data on File. VV-SUP-86970. Takeda Pharmaceutical. 2021.